Original Research

The clinical pharmacology of hirudin - a new anti-coagulant

B. H. Meyer, F. O. Muller, H. G. Luus, N. de la Rey
Suid-Afrikaanse Tydskrif vir Natuurwetenskap en Tegnologie | Vol 11, No 2 | a526 | DOI: https://doi.org/10.4102/satnt.v11i2.526 | © 1992 B. H. Meyer, F. O. Muller, H. G. Luus, N. de la Rey | This work is licensed under CC Attribution 4.0
Submitted: 09 July 1992 | Published: 09 July 1992

About the author(s)

B. H. Meyer,, South Africa
F. O. Muller,, South Africa
H. G. Luus,, South Africa
N. de la Rey,, South Africa

Full Text:

PDF (161KB)

Share this article

Bookmark and Share


Increasing doses of 0,05, 0,1, 0,15 and 0,2 mg/kg of rDNA hirudin, a new anti-coagulant, were given subcutaneously to 20 volunteers (5 per dose) in order to investigate the tolerance and pharmacokinetics of the compound and its effects on coagulation. Hirudin was tolerated very well, the elimination half-life after subcutaneous injections is about 2 hours, about 40% of a given dose is excreted through the kidneys, and an excellent linear relationship was found between the area under the plasma concentration­ time curve and the dose. Hirudin increased partial thromboplastin time in a dose-related fashion.


No related keywords in the metadata.


Total abstract views: 1352
Total article views: 1287

Reader Comments

Before posting a comment, read our privacy policy.

Post a comment (login required)

Crossref Citations

No related citations found.